Nabriva Therapeutics Q3 EPS $(0.24) Beats $(0.28) Estimate, Sales $6.92M Beat $1.05M Estimate

Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 69.62 percent increase over losses of $(0.79) per share

Benzinga · 11/12/2019 21:13

Nabriva Therapeutics (NASDAQ:NBRV) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 69.62 percent increase over losses of $(0.79) per share from the same period last year. The company reported quarterly sales of $6.92 million which beat the analyst consensus estimate of $1.05 million by 559.05 percent. This is a 371.39 percent increase over sales of $1.468 million the same period last year.